CIK 0001789972
- Non-accelerated filer
- Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813879991
- Phone
- +1 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $222,000
- in 2 filings, $222K under 10b5-1 plans
Net −$222,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-01-12 | GADICKE ANSBERT Director | Purchase | +300,000 | $21.00 | $6.3M | 7,913,887 |
| 2021-01-12 | Jovan-Embiricos Morana Director | Purchase | +95,238 | $21.00 | $2.0M | 622,175 |
| 2021-01-12 | Jovan-Embiricos Morana Director | Purchase | +104,762 | $21.00 | $2.2M | 104,762 |
| 2021-01-12 | Trigilio Jeffrey Chief Financial Officer | Purchase | +2,250 | $21.00 | $47K | 2,250 |
| 2021-01-12 | Hughes Owen President and CEO | Purchase | +2,500 | $21.00 | $53K | 506,226 |
Page 2 of 2 · 25 trades